2.335

0.21% -0.005

Cassava Sciences Inc (SAVA)

Overview News Price History Option Chain Financials Why SAVA Down? Discussions Forecast Stock Split Dividend History

Cassava Sciences Inc stock is traded at $2.335, with a volume of 409.08K. It is down -0.21% in the last 24 hours and down -22.68% over the past month. Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

Previous Close:

$2.34

Open:

$2.33

24h Volume:

409.08K

Relative Volume:

0.08

Market Cap:

$112.58M

Revenue:

Net Income/Loss:

$-97.22M

P/E Ratio:

-1.692

EPS:

-1.38

Net Cash Flow:

$-82.44M

1W Performance:

-1.89%

1M Performance:

-22.68%

6M Performance:

-92.27%

1Y Performance:

-90.81%

1-Day Range:

$2.32

$2.375

1-Week Range:

$2.2808

$2.49

52-Week Range:

$2.23

$42.20

Cassava Sciences Inc Stock (SAVA) Company Profile

Name

Cassava Sciences Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

512-501-2444

Address

6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

SAVA's Discussions on Twitter

Compare SAVA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SAVA Cassava Sciences Inc	2.33	112.58M	0	-97.22M	-82.44M	-1.38
VRTX Vertex Pharmaceuticals Inc	474.22	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	715.62	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	651.00	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.97	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.68	28.75B	3.30B	-501.07M	1.03B	-2.1146

Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-26-24	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-08-24	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-16-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-15-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-27-21	Initiated	B. Riley Securities	Buy
Feb-16-21	Reiterated	H.C. Wainwright	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-23-20	Upgrade	H.C. Wainwright	Neutral → Buy
May-18-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-15-20	Downgrade	Maxim Group	Buy → Hold
Jan-10-20	Reiterated	Maxim Group	Buy

View All

Cassava Sciences Inc Stock (SAVA) Latest News

12:08 PM

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire

12:08 PM

10:53 AM

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava - PR Newswire

10:53 AM

12:28 PM

CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire

12:28 PM

Feb 06, 2025

Cassava Sciences, Inc. Sued for Securities Law ViolationsInve - GuruFocus.com

Feb 06, 2025

Perhaps timely catching Cassava Sciences Inc (SAVA) would be a good idea - SETE News

Feb 06, 2025

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Shareholders - GlobeNewswire Inc.

Feb 06, 2025

SAVA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to - The Bakersfield Californian

Feb 06, 2025

Feb 05, 2025

Cassava terminates phase 3 REFOCUS-ALZ trial for simufilam - MSN

Feb 05, 2025

CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - GlobeNewswire Inc.

Feb 05, 2025

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Feb 05, 2025

SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit - PR Newswire

Feb 05, 2025

Investing in Cassava Sciences Inc (SAVA) Is Getting More Attractive - Knox Daily

Feb 05, 2025

Feb 04, 2025

CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - GlobeNewswire Inc.

Feb 04, 2025

Cassava Sciences, Inc. Investors: Please contact the - GlobeNewswire

Feb 04, 2025

Cassava Sciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. - The Bakersfield Californian

Feb 04, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAVA - PR Newswire

Feb 04, 2025

Cassava Sciences, Inc. Class Action: Levi & Korsinsky - GlobeNewswire

Feb 04, 2025

INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire

Feb 04, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava - GlobeNewswire

Feb 04, 2025

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire

Feb 04, 2025